VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

rLSDV-RPV v2RVFH
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004763
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Recombinant capripox-rinderpest vaccine (Ngichabe et al., 2002).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004813
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Cattle
  • RPVgp5 F gene engineering:
    • Type: Recombinant vector construction
    • Description: The vaccine v2RVFH is a recombinant vector vaccine that expresses two proteins including the F protein from the rinderpest virus (Verardi et al., 2002).
    • Detailed Gene Information: Click Here.
  • RPVgp6 H gene engineering:
    • Type: Recombinant protein preparation
    • Description: The vaccine v2RVFH is a recombinant vector vaccine that expresses the H protein from a rinderpest virus (Verardi et al., 2002).
    • Detailed Gene Information: Click Here.
  • Vector: Vaccinia virus vector (Verardi et al., 2002)
  • Preparation: The v2RVFH vaccine was prepared by using a recombinant vaccinia virus vaccine to expresses both the fusion (F) and hemagglutinin (H) genes of rinderpest virus (RPV) under strong synthetic vaccinia virus promoters (Verardi et al., 2002).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Cattle Response

  • Vaccination Protocol: A dose of 105.3 TCID50/ml of the recombinant vaccine, determined previously as an effective dose, was injected subcutaneously in the shoulder region of each animal (Ngichabe et al., 2002).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Two years after vaccination, cattle were challenged with virulent RPV (Ngichabe et al., 2002).
  • Efficacy: In the case of LSDV, all of 4 vaccinated cattle challenged with virulent LSDV at 2 years were completely protected from clinical disease while 2 of 5 vaccinated cattle were completely protected at 3 years. The recombinant vaccine showed no loss of potency when stored lyophylized at 4 degrees C for up to 1 year (Ngichabe et al., 2002).

Cattle Response

  • Host Strain: Zebu cattle
  • Vaccination Protocol: Groups of Zebu cattle (Bos indicus, 2 years old on average) vaccinated intramuscularly (1 ml) with various doses of v2RVFH at the side of the neck. Control groups were also included (Verardi et al., 2002).
  • Immune Response: Intramuscular vaccination of cattle with 108 PFU of v2RVFH provided long-term sterilizing immunity against rinderpest (Verardi et al., 2002).
  • Side Effects: The vaccine is highly safe. Animals vaccinated with v2RVFH did not develop pock lesions and did not transmit the recombinant vaccinia virus to contact animals (Verardi et al., 2002).
  • Challenge Protocol: Animals were challenged subcutaneously (1 ml) at the side of the neck with 103 to 104 TCID50 of the pathogenic Kabete ‘O’ RPV; as little as 1 TCID50 of the virus administered subcutaneously induces clinical rinderpest with 100% mortality in U.S. cattle. Nasal and ocular swabs were taken at 2, 3, 4, and 7 days postchallenge from a group of NVI animals challenged at 4 weeks postvaccination. In addition, prescapular and mesenteric lymph nodes as well as lung, spleen, tonsil, kidney, and heart tissue samples were taken from animals that died following RPV challenge. RPV isolation was attempted from the collected swabs and necropsy samples in primary calf cells (kidney and testis) and Vero cells (Verardi et al., 2002).
  • Efficacy: Cattle vaccinated intramuscularly with as little as 103 PFU of v2RVFH and challenged 1 month later with a lethal dose of RPV were completely protected from clinical disease; the 50% protective dose was determined to be 102 PFU. Animals vaccinated with v2RVFH did not develop pock lesions and did not transmit the recombinant vaccinia virus to contact animals (Verardi et al., 2002).
References References
Ngichabe et al., 2002: Ngichabe CK, Wamwayi HM, Ndungu EK, Mirangi PK, Bostock CJ, Black DN, Barrett T. Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiology and infection. 2002; 128(2); 343-349. [PubMed: 12002554].
Verardi et al., 2002: Verardi PH, Aziz FH, Ahmad S, Jones LA, Beyene B, Ngotho RN, Wamwayi HM, Yesus MG, Egziabher BG, Yilma TD. Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins. Journal of virology. 2002; 76(2); 484-491. [PubMed: 11752138].